Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-06-07
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses its Recursion OS platform, automated labs, and proprietary data to discover and develop medicines internally and with partners.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Drives the Rerating Case
The upside case rests on turning a strong discovery engine into at least one commercially credible medicine and a more repeatable partner model. The stock can rerate meaningfully from here, but only if platform claims become regulatory and clinical facts.

Analysis

Thesis
Recursion is a leveraged bet that cheaper AI will make hypothesis generation abundant while verified biological data, automated experiments, and downstream drug rights stay scarce; if REC-4881 earns a credible registrational path and one more internal asset matures, the company can rerate from cash-backed option value to a product-plus-platform biotech.
Last Economy Alignment
Recursion owns scarce data, lab automation, and workflow integration that become more valuable as generic model access gets cheaper, but the payoff still depends on clinical proof and regulatory progress.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
The upside is a quality shift, not just more discovery activity. A credible late-stage path for the lead rare-disease asset, a second internally generated clinical proof point, and more recurring partner economics would move the business from speculative platform promise toward a hybrid drug creator and discovery infrastructure model. That supports a meaningful rerating without needing a heroic many-asset success case.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not that AI stops helping discovery; it is that faster discovery never converts into repeatable human proof. If REC-4881 does not secure a credible registrational path, if follow-on internal assets stay early or inconclusive, or if burn forces financing before stronger validation arrives, Recursion can remain a cash-backed option story rather than compounding into a higher-quality biotech franchise.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.43
They control a hard-to-copy loop of proprietary data, automated labs, and drug programs, so cheaper AI should help them more than a thin software wrapper. The threat is simple: if those faster experiments do not become real clinical wins, the advantage stays interesting but not valuable.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case